Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune system.

导出 LinkOut

翻译打印收藏纠错

作者： Sjoerd,Klarenbeek ^[1] ; Chris W,Doornebal ^[2] ; Sjors M,Kas ^[3] ; Nicola,Bonzanni ^[2] ; Jinhyuk,Bhin ^[4] ; Tanya M,Braumuller ^[5] ; Ingrid,van der Heijden ^[1] ; Mark,Opdam ^[2] ; Philip C,Schouten ^[2] ; Kelly,Kersten ^[6] ; Roebi,de Bruijn ^[7] ; Daniel,Zingg ^[1] ; Julia,Yemelyanenko ^[2] ; Lodewyk F A,Wessels ^[6] ; Karin E,de Visser ^[1] ; Jos,Jonkers ^[2]

作者单位： Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. ^[1] Oncode Institute, Utrecht, The Netherlands. ^[2] Experimental Animal Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. ^[3] Division of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. ^[4] Department of Anesthesiology, Amsterdam UMC, Amsterdam, The Netherlands. ^[5] Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands. ^[6] ENPICOM, 's-Hertogenbosch, The Netherlands. ^[7] Department of EEMCS, Delft University of Technology, Delft, The Netherlands. ^[8]

关键词 Invasive lobular carcinoma immune system mTOR mouse model therapy